Comparison of neurotoxicity following repeated administration of l- dopa, d-dopa, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors

Cell Transplantation

Volumn 6, Issue 3, 1997, Pages 309-315

  Alexander, T ^b   Sortwell, C E ^b   Sladek, C D ^b   Roth, R H ^b   Steece Collier, K ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b NONE

Author keywords

Neural grafting; Oxidative stress; Parkinson's disease; Substantia nigra

Indexed keywords

DOPA; DOPAMINE; LEVODOPA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; EMBRYO; FEMALE; MESENCEPHALON; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STRAIN DIFFERENCE; SUBSTANTIA NIGRA;

ANIMALS; CELLS, CULTURED; DOPAMINE; DOPAMINE AGENTS; FEMALE; FETUS; LEVODOPA; MESENCEPHALON; NEURONS; NEUROTOXINS; PREGNANCY; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MARTES PENNANTI;

EID: 0030977070     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0963-6897(97)00031-6     Document Type: Article

References (34)

1. Adams, C.E.; Hoffman, A.F.; Hudson, J.L.; Hoffer, B.J.; Boyson, S.J. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats. Exp. Neurol. 130:261-268; 1994.
2. Ambani, L.M.; Van Woert, W.H.; Murphy, S. Brain peroxidase and catalase in Parkinson's disease. Arch. Neurol. 32:114-118; 1975.
3. Aust, S.D.; White, B.C. Iron chelation prevents tissue injury following ischemia. Adv. Free Radic. Biol. Med. 1: 1-17; 1985.
4. Blunt, S.B.; Jenner, P.; Marsden, C.D. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts. Neuroscience 40:453-464; 1991.
5. Chalmers, R.M.E.; Fine, A. The influence of l-dopa on survival and outgrowth of fetal ventral mesencephalic dopaminergic neurons in vitro and after intracerebral transplantation. In: Lindvall, O.; Bjorklund, A.; Widner, H., eds. Intracerebral transplantation in movement disorders. New York: Elsevier; 1992:333-342.
6. Felten, D.L.; Felten, S.Y.; Steece-Collier, K.; Clemens, J.A. Age-related decline in the dopaminergic nigrostriatal system: The oxidative hypothesis and protective strategies. Ann. Neurol. 32:133-136; 1992.
7. Goetz, G.G.; DeLong, M.R.; Penn, R.D.; Bakay, R.A.E. Neurosurgical horizons in Parkinson's disease. Neurology 43:1-7; 1993.
8. Goodale, K.E.; Moore, D.B. 6-Hydroxydopamine-induced dopaminergic receptor supersensitivity: Studies with d-and l-dopa. In: Jonsson, G., ed. Chemical tools in catecholamine research. Amesterdam: North-Holland; 1975:343-347.
9. Graham, D.L. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:633-643; 1978.
10. Graham, D.C. Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5:83-95; 1984.
11. Hitchcock, E.R.; Clough, C.; Hughes, R.; Kenny, B. Embryos and Parkinson's disease. Lancet 318:50-51; 1988.
12. Kish, S.J.; Morito, C.; Hornykiewicz, O. Iutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58:343-346; 1985.
13. Kontur, P.J.; Marek, K.L.; Redmond, D.E.; Roth, R.H. Adverse effects of L-dopa and dopamine receptor agonists on cultured rat mesencephalic dopamine neurons. Soc. Neurosci. Abstr. 19:1049; 1993.
14. Kordower, J.H.; Freeman, T.B.; Snow, B.; Vingerhoets, F.J.G.; Mufson, E.J.; Sanberg, P.R.; Hauser, R.A.; Smith, D.A.; Nauert, G.M.; Perl, D.P.; Olanow, C.W. Neuropathological evidence of graft survival and striatum reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332:1118-1124; 1995.
15. Lees, A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J. 311:1602-1607; 1995.
16. Ling, Z.D.; Pieri, S.C.; Carvey, P.M. Comparison of the neurotoxicity of Dopa stereoisomers in cultured DA neurons Clin. Neuropharmacol. 19(4):360-5, 1996.
17. Mena, M.A.; Pardo, B.; Casarejos, M.J.; Fahn, S.; de Yebenes, J.G. Neurotoxicity of levodopa on catecholaminerich neurons. Movement Disord. 7:23-31; 1991.
18. Mytilineou, C.; Han, S.K.; Cohen, G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J. Neurochem. 61:1470-1478; 1993..
19. Notter, M.F.D.; Gash, D.M.; Sladek, C.D.; Sharoun, S.L. Vasopressin in reaggregated cell cultures of the developing hypothalamus. Brain Res. Bull. 12:307-313; 1984.
20. Olson, L.; Seiger, A. Early prenatal ontogeny of central monoamine neurons in the rat: Fluorescence histochemical observations. Z. Anat. Entwickl. Gesch. 137:301-316; 1972.
21. Paino, C.L.; Pardo, B.; Mena, M.A. L-Dopa toxicity in embryonic mesencephalic neurons prevented by ascorbic acid. In: Freed, W.J.; Rosenstein, J.M., eds. Restorative neurology and neuroscience, IVth international symposium on neural transplantation. New York: Elsevier; 1991: 167.
22. Pardo, B.; Mena, M.A.; Yebenes, J.G. L-DOPA inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J. Neurochem. 64:576-582; 1995.
23. Perry, T.L.; Godin, D.V.; Hansen, S. Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:305-310; 1982.
24. Perry, T.L.; Yong, V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67:269-274; 1986.
25. Riachi, N.J.; Behmand, R.A.; Harik, S.I. Correlation of MPTP neurotoxicity in vivo with oxidation of MPTP by the brain and blood-brain barrier in vitro in five rat strains. Brain Res. 555:19-24; 1991.
26. Schinelli, S.; Paolillo, M.; Quartieri, M.; Santagostino, G. Dopamine synthesis, uptake and metabolism in embryonic rat mesencephalic cultures. Pharmacol. Res. 28:265-276; 1993.
27. Steece-Collier, K.; Sladek, J.R., Jr. Neural transplantation in the dopamine system: Basic research. In: Fahn, S.; Marsden, C.D., eds. Movement disorders, 3. Oxford: Butterworth-Heinemann; 1994:200-225.
28. Steece-Collier, K.; Collier, T.J.; Sladek, CD.; Sladek, J.R., Jr. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp. Neurol. 110: 201-208; 1990.
29. Steece-Collier, K.; Yurek, D.M.; Collier, T.J.; Junn, F.S.; Sladek, J.R., Jr. The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdrawal of chronic dosing. Brain Res. 676:404-408; 1995.
30. Steece-Collier, K.; Alexander, T.; Sortwell, C.E.; Sladek, C.D. Identification of variables associated with levodopainduced toxicity in embyronic dopamine neurons. Am. Soc. Neural Transplant. 3:11; 1996.
31. Tanaka, M.; Sotomatsu, A.; Kanai, H.; Hirai, S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J. Neurol. Sci. 101:198-202; 1991.
32. Valchar, M.; Hanbauer, I. Rat mesencephalic neuronal cells cultured for different periods as a model of dopamine transporter ontogenesis. Mol. Neurobiol. 11:111-119; 1995.
33. Yurek, D.; Steece-Collier, K.; Collier, T.J.; Sladek, J.R. Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting. Exp. Brain Res. 86:97-107; 1991.
34. Zigmond, M.; Hastings, T.; Abercrombie, E. Neurochemical responses to 6-hydroxy-dopamine and L-dopa therapy: Implications for Parkinson's disease. Ann. NY Acad. Sci. 648:71-86; 1992.